ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss.
Therapy Area
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC
ASCO26: In vivo oncology approaches continue to show promise
Emerging therapies for CNS tumours: key clinical trial updates to watch at ASCO 2026
ATS 2026: Insmed shines in bronchiectasis with spotlight on Brinsupri
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer
ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise
